抗胆固醇药对神经性下尿路功能障碍患者的认知功能的影响:叙述性综述
Blayne Welk1,2
1Department of Surgery, Western University, London, Ontario, Canada.
概括
对过度活跃膀 (OAB) 的抗胆固醇药物可能会增加神经性下尿路功能障碍 (NLUTD) 患者的认知风险. 奥西布丁宁和托尔特罗丁的风险较高,而新药和在脊柱裂儿童中使用的药物似乎更安全.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 神经性下尿路功能障碍 (NLUTD) 影响有脊髓损伤 (SCI),多发性硬化症 (MS) 和痴呆等疾病的患者.
- 过度活性膀 (OAB) 药物,特别是抗胆固醇药物,经常用于NLUTD管理.
- 认知副作用是抗胆固醇药物使用的已知问题,特别是在长期治疗 (>90天) 时.
研究的目的:
- 审查抗胆固醇药物和NLUTD患者的认知变化之间的关联.
- 在各种NLUTD群体中评估不同抗胆固醇OAB药物的认知安全性.
- 识别潜在的风险,并为临床实践提供有关OAB药物选择的信息.
主要方法:
- 现有文献的叙述性审查.
- 对检查抗胆固醇OAB药物在SCI,多发性硬化,痴呆,脊柱裂 (SB),帕金森病和中风患者中的使用研究的分析.
- 综合了与特定抗胆固醇药物相关的认知结果的发现.
主要成果:
- 氧化丁尼和托尔特罗丁在SCI,MS和痴呆症患者中显示出潜在的认知障碍.
- 对SB儿童的研究表明,使用索利芬素,费索托罗丁或氧丁宁没有显著的认知变化.
- ,达里芬素和费索托罗丁在帕金森病和中风患者中没有显著的认知影响.
结论:
- 与较新的抗胆固醇药物相比,oxybutynin和tolterodine在NLUTD患者中可能具有更高的认知风险.
- 目前的证据表明,抗胆固醇OAB药物在SB的儿童中是认知安全的.
- 需要进一步的研究来确认认知安全性,特别是考虑到NLUTD人群的高暴露率,倡导更安全的药物选择.
相关概念视频
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
2.3K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.3K
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.9K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.9K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.8K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.8K
01:24Cholinergic Antagonists: Pharmacokinetics
1.1K
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
1.1K
01:28Cholinergic Antagonists: Pharmacological Actions
1.9K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.9K
01:26Cholinergic Antagonists: Therapeutic Uses
1.7K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.7K